Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections.

ABSTRACT: Molds are ubiquitous in the environment, and immunocompromised patients are at substantial risk of morbidity and mortality due to their underlying disease and the resistance of pathogenic molds to currently recommended antifungal therapies. This combination of weakened-host defense, with limited antifungal treatment options, and the opportunism of environmental molds renders patients at risk and especially vulnerable to invasive mold infections such as Aspergillus and members of the Order Mucorales. Currently, available antifungal drugs such as azoles and echinocandins, as well as combinations of the same, offer some degree of efficacy in the prevention and treatment of invasive mold infections, but their use is often limited by drug resistance mechanisms, toxicity, drug-drug intera

SUBMITTER: Angulo DA 

PROVIDER: S-EPMC9695964 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature